RLY-2608: An Allosteric Pan-Mutant-Selective PI3Kα Inhibitor Without Hyperglycemia in Preclinical Models

RLY-2608

oral allosteric pan-mutant isoform-selective PI3Kα inhibitor Ph. I for PIK3CA mutant cancers from DEL screen for mutant-specific allosteric inhibitors Cancer Discov., November 2023 D.E. Shaw Research / Relay Therapeutics

Authors:

Shaima Qunies,

Yan Chen

Editor:

Rory McAtee

RLY-2608: An Allosteric Pan-Mutant-Selective PI3Kα Inhibitor Without Hyperglycemia in Preclinical Models

RLY-2608

Other molecules you may be interested in